ProMIS公布PMN310在人体脑脊液中降低毒性淀粉样寡聚体的早期证据

ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, reported the first human evidence that its lead Alzheimer's drug candidate, PMN310, can reduce toxic amyloid-beta oligomers in cerebrospinal fluid. The findings were presented at the AAIC 2026 conference.
Phase 1a Results
In healthy volunteers, a single dose-dependent reduction in amyloid-beta oligomer detectable in cerebrospinal fluid at both 3 and 29 days after dosing. This represents one of the first quantitative demonstrations of treatment-related oligomer reduction in humans.
Scientific Significance
Amyloid-beta oligomers (AßOs) are considered more toxic than the plaque deposits and are believed to play a central role in Alzheimer's disease progression. By selectively targeting oligomers while avoiding plaque, PMN310 may reduce off-target binding and limit side effects such as ARIA, which are associated with plaque-binding antibodies.
-Oligomer reductions: In the Phase 1a trial, PMN310 showed a dose-dependent reduction of toxic AßO in CSF.
-Strict oligomer selectivity: Laboratory assays confirmed PMN310 binds strongly to oligomers without interacting with monomers, plaques, or vascular deposits, supporting a differentiated safety profile.
-Favorable pharmacokinetics and tolerability: PMN310 was generally well-tolerated in health volunteers, with CSF concentrations rising in a dose-dependent manner and half-life of approximately 27 days.
-Preclinical memory preservation: In Alzheimer's mouse model, PMN310 preserved memory and learning performance, reinforcing its potential clinical benefit.
Management Commentary
CEO Neil Warma said the data provide direct evidence that PMN310 reached the brain and engaged its intended target. Chief Development Officer, Dr. Johanne Kaplan added that the results support PMN310's differentiated mechanism of action and its potential to improve both efficacy and safety in Alzheimer's treatment.
Next Step
ProMIS plans to use this assay in its ongoing PRECISE-AD Phase 1b trial, which is evaluating PMN310 in Alzheimer's patients. Six-month blinded interim data are expected in the coming weeks. Top line unblinded results are expected in early Q1 2027. PMN has traded between $6.27 and $39.75 over the past year. The stock closed Monday's trading at $12.80, down 10.18%. In pre-market trading the stock is at $14.40, up 12.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.